Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology
Over the last decade there has been a bottleneck in the introduction of new validated cancer metabolic biomarkers into clinical practice. Unfortunately, there are no biomarkers with adequate sensitivity for the early detection of cancer, and there remain a reliance on cancer antigens for monitoring treatment. The need for new diagnostics has led to the exploration of untargeted metabolomics for discovery of early biomarkers of specific cancers and targeted metabolomics to elucidate mechanistic aspects of tumor progression. The successful translation of such strategies to the treatment of cancer would allow earlier intervention to improve survival. We have reviewed the methodology that is being used to achieve these goals together with recent advances in implementing translational metabolomics in cancer.
R01CA158328; P30ES023720; P30ES013508; P30CA016520 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
P30CA016520 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
P30ES013508 / NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
Resource Type
Journal article
Language
English
Academic Unit
A.J. Drexel Autism Institute
Web of Science ID
WOS:000362033300002
Scopus ID
2-s2.0-84942876036
Other Identifier
991019167868904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: